Eisai - Pipeline - Products - Performance - Potential - Market Research Reports

Printer Friendly

Printed from http://www.researchandmarkets.com/reports/455662

Eisai - Pipeline - Products - Performance - Potential

Description:

Headquartered in Japan, Eisai operates in two main business areas: Pharmaceuticals, including ethical drugs, OTC products and diagnostics; and Others, which comprises pharmaceutical production systems and equipment. Eisai has clinical research bases in North America, Europe, Asia and Japan, and employs over 9,600 people worldwide. Eisai sells products within the following therapeutic areas: neurology; gastroenterology; cardiovascular and respiratory; anti-infectives; metabolic; and diagnostics. It is now focusing its research and development efforts on neurology, gastroenterology and oncology/critical care.

Foreign subsidiaries and operations generated 60.9 per cent of Eisai’s sales in fiscal 2007 (compared to 53 per cent the previous year), and the company continues to strive to create efficient global management. Much of Eisai’s globalisation has been generated through the success of its two core products: Aricept, for the treatment of Alzheimer’s disease, and Aciphex/Pariet, a therapy for gastric acid-related conditions. In order to maximise the value of these products abroad, Eisai recognised the need for strategic alliances with companies with greater experience in foreign markets.

Therefore, Eisai has been marketing Aricept in various markets with the pharmaceutical giant Pfizer since November 1994, and Aciphex/Pariet has benefited from co-marketing with Janssen Pharmaceutica (a major subsidiary of Johnson & Johnson) in both European and US markets since January 1997. Such is Eisai’s confidence in the recognition and standing of these products, and in its own US operations, the company assumed total control over the marketing of Aricept in the US in September 2005, and of Aciphex/Pariet, earlier in January 2004. Eisai is now targeting the emerging markets of China and India and, in October 2004, established the first Japanese pharmaceutical subsidiary in India, followed in March 2007, by the establishment of an active pharmaceutical ingredient R&D and manufacturing subsidiary, Eisai Pharmatechnology Manufacturing Pvt Ltd in Vishakhapatnam, which will commence operations in fiscal 2010. Eisai will be committing resources to these markets on a priority basis, thus laying the foundations for future business.

Both of the aforementioned products will be the key growth drivers for Eisai in the short-term, however, pending patent expirations (25th November 2010, for Aricept, and May 2013, for Aciphex/Pariet) are a serious concern for the company which will need to be addressed. Eisai has responded by targeting a new therapeutic of interest, oncology and critical care. Eisai believes this field has significant levels of unmet needs and therefore, the potential to generate growth in the long-term. Eisai’s confidence and dedication to this strategy has been demonstrated by its recent acquisitions of Morphotek and MGI Pharma, two biopharmaceutical companies with extensive history in the field of oncology. Eisai has also purchased rights to five oncology products from Ligand Pharmaceuticals.

Contents:

EXECUTIVE SUMMARY
A detailed and comprehensive overview of current financial position, company strategy, product and pipeline analysis.

THERAPEUTIC AREA FOCUS
Key product analysis and forecasting

Neurology
Aricept (donepezil)
Inovelon (rufinamide)
Methycobal/Nabolin S (mecobalamin)
Neurobloc (botulinum toxin type B Injectable Solution)

Gastroenterology
Aciphex/Pariet (rabeprazole)
Selbex (teprenone)

Metabolic
Glucagon G Novo (glucagon)
KayTwo/Glakay (menatetrenone)

Diagnostics
Iomeron (iomeprol)

Cardiovascular and Respiratory
Azeptin (azelastine)
Nitorol-R (isosorbide dinitrate)

Oncology
ONTAK/ONZAR (denileukin diftitox)
Panretin (alitretinoin)
Targretin (bexarotene)

OPERATIONAL DATA
A wealth of background and detail
A full 5-year financial performance assessment
Key corporate events
Key agreements
Infrastructure
Subsidiaries and joint ventures

Summary:

This new strategic analysis report Eisai: Pipeline - Products - Performance - Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. 4D Pharma reports are updated with the latest data on a continuing basis and the full report is released quarterly. Once a year the report undergoes a major review in line with the company's year end. Buyers of the print/pdf editions will receive the latest version and quarterly updated reports for a year. Buyers of the web edition receive online access for one year via an easy-to-use interface with fast navigation and a full text search facility. All formats are the same price.

Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/455662

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2
Printed 05/09/2008 15:28:16

Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com

Order information

Please verify that the product information is correct and select the format you require.


Product Name:
Eisai - Pipeline - Products - Performance - Potential
Web Address:
http://www.researchandmarkets.com/reports/455662
Office Code:
OCHHGJROORQ

Report formats

Please enter the quantity of the report format you require.

Format	Quantity	Price
Electronic (PDF) - Single User		€895.00
Hard Copy		€895.00 + EUR€ 50.00 Shipping/Handling *
Electronic (Online Access)		€895.00

* Shipping/Handling is only charged once per order.

Contact information

Please enter all the information below in BLOCK CAPITALS.


	First Name:	Last Name:
	Email Address:
	Job Title:
	Organisation:
	Address:
	City:
	Postal/Zip Code:
	Country:
	Phone Number:
	Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World

Page 2 of 2
Printed 05/09/2008 15:28:16

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

	American Express
	Diners Club
	Master Card
	Visa


Cardholder Name:

Expiry Date:	/

Card Number:

CVV Security Code:

Issue Date:	/ (Diners Club only)

Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:


Account number:	83313083
Sort code:	98-53-30
Swift code:	ULSBIE2D
IBAN number:	IE78ULSB98533083313083
Bank Address:	Ulster Bank, 27-35 Main St, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:
	Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World